BRCA2 is altered in 6.25% of ovarian carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 Mutation (somatic) and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (0 open) [5].

BRCA2 is altered in 4.48% of breast carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRCA2 Mutation (somatic) and breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

BRCA2 is altered in 13.64% of primary peritoneal carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 Mutation (somatic) and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [5].

BRCA2 is altered in 5.45% of malignant solid tumor patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 Mutation (somatic) and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

BRCA2 is altered in 1.82% of fallopian tube carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 Mutation (somatic) and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [5].

BRCA2 is altered in 9.74% of melanoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 8.33% of bladder carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 5.79% of esophageal squamous cell carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 7.76% of malignant uterine neoplasm patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 8.41% of colorectal carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 6.39% of gastric adenocarcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 4.85% of head and neck carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 4.54% of non-small cell lung carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 4.55% of lung carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 4.89% of adenocarcinoma of the gastroesophageal junction patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 5.2% of cancer patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 5.1% of gallbladder carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 5.08% of pancreatic carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 6.61% of prostate carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 4.47% of invasive breast carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 3.87% of bile duct carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 2.89% of cervical carcinoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 is altered in 2.65% of soft tissue sarcoma patients [4].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].